REGNÂ – Regeneron Pharmaceuticals, Inc.
Float Short %
2.89
Margin Of Safety %
-4
Put/Call OI Ratio
0.51
EPS Next Q Diff
-1.57
EPS Last/This Y
2.33
EPS This/Next Y
-6.73
Price
642.57
Target Price
756.65
Analyst Recom
1.69
Performance Q
12.7
Relative Volume
0.76
Beta
0.31
Ticker: REGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-06 | REGN | 584.91 | 0.63 | 0.78 | 57410 |
| 2025-10-07 | REGN | 582.85 | 0.64 | 0.13 | 58296 |
| 2025-10-08 | REGN | 563 | 0.63 | 0.57 | 59128 |
| 2025-10-09 | REGN | 569.72 | 0.63 | 0.45 | 60912 |
| 2025-10-10 | REGN | 564.01 | 0.63 | 0.66 | 61488 |
| 2025-10-13 | REGN | 557.2 | 0.65 | 0.77 | 60207 |
| 2025-10-14 | REGN | 572.64 | 0.65 | 0.24 | 61722 |
| 2025-10-15 | REGN | 575.42 | 0.65 | 0.09 | 62035 |
| 2025-10-16 | REGN | 568.74 | 0.65 | 0.31 | 62306 |
| 2025-10-17 | REGN | 578.3 | 0.64 | 0.32 | 62687 |
| 2025-10-20 | REGN | 576.53 | 0.51 | 0.64 | 54224 |
| 2025-10-21 | REGN | 579.68 | 0.52 | 0.41 | 55135 |
| 2025-10-22 | REGN | 585.27 | 0.51 | 0.47 | 55456 |
| 2025-10-23 | REGN | 575.7 | 0.51 | 3.42 | 55716 |
| 2025-10-24 | REGN | 577.87 | 0.52 | 1.31 | 56312 |
| 2025-10-27 | REGN | 584.48 | 0.51 | 0.97 | 54377 |
| 2025-10-28 | REGN | 655.29 | 0.54 | 0.44 | 57658 |
| 2025-10-29 | REGN | 653.16 | 0.54 | 0.43 | 60347 |
| 2025-10-30 | REGN | 654.06 | 0.55 | 0.51 | 60732 |
| 2025-10-31 | REGN | 651.66 | 0.55 | 0.57 | 60868 |
| 2025-11-03 | REGN | 642.46 | 0.51 | 0.49 | 54889 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-06 | REGN | 584.91 | -22.3 | 59.6 | 39.41 |
| 2025-10-07 | REGN | 583.20 | -22.8 | 176.9 | 39.53 |
| 2025-10-08 | REGN | 562.91 | -22.8 | 5.5 | 39.53 |
| 2025-10-09 | REGN | 569.73 | -22.8 | 256.3 | 39.53 |
| 2025-10-10 | REGN | 564.30 | -22.8 | 144.0 | 39.53 |
| 2025-10-13 | REGN | 557.21 | -22.4 | 125.5 | 39.63 |
| 2025-10-14 | REGN | 572.97 | -23.0 | 350.3 | 39.55 |
| 2025-10-15 | REGN | 576.78 | -23.0 | 239.0 | 39.56 |
| 2025-10-16 | REGN | 569.19 | -23.0 | 129.0 | 39.56 |
| 2025-10-17 | REGN | 578.27 | -22.5 | 287.2 | 39.68 |
| 2025-10-20 | REGN | 576.77 | -22.5 | 186.3 | 39.68 |
| 2025-10-21 | REGN | 579.32 | -22.7 | 223.0 | 39.67 |
| 2025-10-22 | REGN | 584.74 | -22.7 | 250.1 | 39.67 |
| 2025-10-23 | REGN | 576.01 | -22.5 | 115.8 | 39.74 |
| 2025-10-24 | REGN | 578.05 | -22.8 | 221.1 | 39.87 |
| 2025-10-27 | REGN | 584.29 | -22.8 | 259.3 | 39.87 |
| 2025-10-28 | REGN | 654.48 | -22.6 | 852.6 | 39.98 |
| 2025-10-29 | REGN | 652.76 | -22.6 | 183.8 | 39.98 |
| 2025-10-30 | REGN | 654.04 | -11.5 | -67.7 | 43.29 |
| 2025-10-31 | REGN | 651.80 | -11.5 | -96.4 | 43.29 |
| 2025-11-03 | REGN | 642.57 | -11.5 | -1428.2 | 43.23 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-06 | REGN | 0.00 | -3.75 | 2.92 |
| 2025-10-07 | REGN | 0.00 | -3.75 | 2.92 |
| 2025-10-08 | REGN | 0.00 | -3.75 | 2.92 |
| 2025-10-09 | REGN | 0.00 | -3.75 | 2.92 |
| 2025-10-10 | REGN | 0.00 | -3.75 | 2.70 |
| 2025-10-13 | REGN | 0.00 | -3.66 | 2.70 |
| 2025-10-14 | REGN | 0.00 | -3.66 | 2.70 |
| 2025-10-15 | REGN | 0.00 | -3.66 | 2.70 |
| 2025-10-16 | REGN | 0.00 | -3.66 | 2.70 |
| 2025-10-17 | REGN | 0.00 | -3.66 | 2.70 |
| 2025-10-20 | REGN | 0.00 | -3.67 | 2.70 |
| 2025-10-21 | REGN | 0.00 | -3.67 | 2.70 |
| 2025-10-22 | REGN | 0.00 | -3.67 | 2.70 |
| 2025-10-23 | REGN | 0.00 | -3.67 | 2.70 |
| 2025-10-24 | REGN | 0.00 | -3.67 | 2.70 |
| 2025-10-27 | REGN | 0.00 | -3.33 | 2.87 |
| 2025-10-28 | REGN | 0.00 | -3.33 | 2.87 |
| 2025-10-29 | REGN | 0.00 | -3.33 | 2.87 |
| 2025-10-30 | REGN | 0.00 | -3.33 | 2.87 |
| 2025-10-31 | REGN | -0.17 | -3.33 | 2.87 |
| 2025-11-03 | REGN | -0.17 | -3.40 | 2.89 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
11.83
Avg. EPS Est. Current Quarter
10.68
Avg. EPS Est. Next Quarter
10.26
Insider Transactions
-0.17
Institutional Transactions
-3.4
Beta
0.31
Average Sales Estimate Current Quarter
3737
Average Sales Estimate Next Quarter
3396
Fair Value
616.82
Quality Score
99
Growth Score
65
Sentiment Score
63
Actual DrawDown %
47
Max Drawdown 5-Year %
-59.7
Target Price
756.65
P/E
15.38
Forward P/E
15.04
PEG
4.59
P/S
4.74
P/B
2.18
P/Free Cash Flow
15.99
EPS
41.77
Average EPS Est. Cur. Y​
43.23
EPS Next Y. (Est.)
36.5
Target Price Estimates Raised
17
Target Price Estimates Lowered
Profit Margin
32.13
Relative Volume
0.76
Return on Equity vs Sector %
-10.9
Return on Equity vs Industry %
2.4
EPS 1 7Days Diff
3.4
EPS 1 30Days Diff
3.83
EBIT Estimation
-1428.2
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15222
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGNÂ – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGNÂ – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGNÂ – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGNÂ – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading